The Clinical Repositioning of Sleep
For most of clinical medicine's history, sleep was treated as background — something patients either got enough of or didn't, with limited therapeutic relevance beyond the prescription of hypnotics for insomnia. That framing has changed significantly over the past decade. Sleep medicine has emerged as a distinct and rapidly expanding discipline, driven by a convergence of epidemiological data, mechanistic research, and a growing recognition that sleep is not a passive state of rest but an active and essential biological process that underpins virtually every system in the body.
The scale of the problem is not trivial. The World Health Organisation has identified insufficient sleep as a global public health epidemic. In the United States, approximately 35% of adults report regularly sleeping fewer than the recommended seven hours per night.1 In adolescents, rates of insufficient sleep exceed 70%. The economic cost in reduced productivity, healthcare utilisation, and accident risk runs to hundreds of billions annually across developed nations.
Sleep deprivation does not simply cause fatigue. It disrupts hormonal axes, impairs metabolic regulation, damages gut integrity, dysregulates immune function, accelerates biological ageing, and increases risk across virtually every major chronic disease category. Understanding these pathways is no longer optional for practitioners working in functional, lifestyle, or preventive medicine — it is foundational.
Sleep medicine encompasses the clinical management of sleep disorders — insomnia, sleep apnoea, restless legs syndrome, narcolepsy — and the broader study of how sleep quality and quantity affect systemic health. This review focuses primarily on the latter: the downstream effects of insufficient or disrupted sleep on physiological systems, as this is the domain most relevant to functional medicine practice.
The Gut-Brain Axis: Bidirectional and Sleep-Sensitive
The gut-brain axis — the bidirectional communication network between the central nervous system and the gastrointestinal tract — has emerged as one of the most clinically significant interfaces in functional medicine. What is now becoming clear is that this axis is exquisitely sensitive to sleep disruption, and that the relationship is genuinely bidirectional: sleep affects the gut, and the gut affects sleep.
A landmark 2025 review published in Brain Medicine established the microbiota-gut-brain axis as a critical pathway in understanding and potentially treating sleep disorders.2 The gut microbiome communicates with the brain through multiple routes simultaneously: direct neuronal pathways via the vagus nerve, immune system signalling through cytokines and inflammatory mediators, and the production of bioactive metabolites — including short-chain fatty acids (SCFAs), neurotransmitter precursors, and neuroactive compounds — that can cross the blood-brain barrier and directly modulate sleep-wake regulation.
The evidence for sleep's effects on microbiome composition is equally compelling. Holzhausen et al. (2023) found that greater variability in sleep duration and lower sleep efficiency were associated with reduced microbial richness and diversity, as well as changes in specific microbial taxa.3 In elderly men, healthier sleep patterns correlated with greater abundance of butyrate-producing bacteria — a finding with significant implications for gut barrier integrity, systemic inflammation, and metabolic health. A separate study found that shorter sleep duration was associated with reduced secretion of defensin-5, gut dysbiosis, and decreased SCFA production, indicating impaired homeostasis of the entire gut-brain axis.3
A 2024 systematic review in Nutrients (Dos Santos and Galiè) examined the microbiota-gut-brain axis in the context of both sleep disorders and metabolic syndrome, finding shared host-microbial biomarkers across both conditions — suggesting a common mechanistic pathway linking disrupted sleep, gut dysbiosis, and cardiometabolic risk.4 This is not coincidental overlap; it represents a biologically coherent chain of causation that functional medicine practitioners are uniquely positioned to address at multiple points simultaneously.
The Tryptophan-Serotonin-Melatonin Pathway
One of the most clinically relevant microbiome-sleep connections operates through tryptophan metabolism. Approximately 90% of the body's serotonin is produced in the gut, and serotonin is the direct precursor to melatonin — the principal hormone governing circadian rhythm and sleep onset. The gut microbiome plays a significant role in tryptophan availability and serotonin synthesis; dysbiosis can therefore impair melatonin production independently of any central nervous system pathology.
This pathway has direct therapeutic implications. Santamarina et al. (2024) reported that a nutraceutical intervention remodelling the microbiota increased production of SCFAs and peripheral serotonin, with measurable improvements in sleep quality outcomes.3 A 2025 double-blind RCT (Liu et al.) found that supplementation with Bifidobacterium animalis subsp. lactis BLa80 improved Pittsburgh Sleep Quality Index scores, promoted greater Bifidobacterium abundance, and modulated metabolic pathways linked to GABA production — a key inhibitory neurotransmitter involved in sleep regulation.3
The probiotic and prebiotic intervention literature for sleep improvement is promising but remains early-stage. Most trials are small, short in duration, and heterogeneous in strains and protocols. The direction of effect is consistent, but effect sizes are modest, and translation to specific clinical recommendations requires further large-scale RCTs. Practitioners should frame microbiome-targeted sleep interventions as adjunctive and mechanistically plausible rather than first-line treatments.
Hormonal Health: The Endocrine Consequences of Sleep Disruption
The endocrine system is profoundly sensitive to sleep. Sleep is not a period of hormonal quiescence — it is when some of the most important hormonal events of the 24-hour cycle occur. Growth hormone secretion peaks during slow-wave sleep. Testosterone synthesis in men is strongly linked to sleep duration and quality. Cortisol follows a diurnal pattern calibrated by the sleep-wake cycle. Disrupting sleep does not simply shift these rhythms — it dysregulates them in ways that compound across time to produce measurable clinical harm.
Cortisol and the HPA Axis
Cortisol is normally at its lowest around midnight and rises steeply through the early morning hours, peaking around 8–9am. This rhythm is calibrated to the sleep-wake cycle. After just six days of sleep restriction to four hours per night, the rate of cortisol decline in the early evening was approximately six times slower in sleep-restricted subjects compared to fully rested controls.5 This elevation of evening cortisol directly promotes insulin resistance, suppresses growth hormone, and maintains a state of sympathetic dominance that makes subsequent sleep lighter and less restorative — a self-perpetuating cycle.
A 2024 interventional study published in PMC provided mechanistic proof of this pathway by using a dual hormone clamp to prevent both the flattening of the diurnal cortisol slope and the reduction in testosterone that occur with sleep restriction. By correcting these hormonal disturbances pharmacologically, the researchers mitigated the development of insulin resistance from sleep restriction by at least 50% — directly identifying abnormal cortisol and testosterone signalling as major mechanisms by which insufficient sleep causes metabolic harm.6
Testosterone and Male Hormonal Health
The relationship between sleep and testosterone is one of the most consistently demonstrated findings in sleep endocrinology. A 2026 review in Reviews in Endocrine and Metabolic Disorders found that sleep deprivation reliably reduces testosterone concentrations through multiple converging mechanisms: HPA axis activation leading to elevated cortisol suppresses GnRH and LH secretion, with simultaneous direct impairment of Leydig cell function.7 The clinical consequences extend beyond reproductive health — reduced testosterone is associated with increased systemic inflammation, insulin resistance, accelerated biological ageing, and reduced lean muscle mass.
Growth Hormone, Repair and Metabolic Function
The majority of daily growth hormone secretion in adults occurs during slow-wave sleep (stage N3). GH is not merely a growth factor — it plays a central role in tissue repair, lipid metabolism, glucose regulation, and immune function. Sleep deprivation reduces slow-wave sleep duration and disrupts GH secretion in a dose-dependent pattern: the more severely and chronically sleep is disrupted, the more profoundly GH secretion is impaired.8 For practitioners working with patients experiencing poor recovery from exercise, unexplained fatigue, or impaired body composition despite appropriate training and nutrition, sleep architecture — specifically slow-wave sleep duration — is a clinical variable that warrants direct assessment.
Metabolism: Sleep as a Metabolic Regulator
The metabolic consequences of sleep disruption are among the most robustly evidenced in the field. A comprehensive 2024 narrative review in Diabetes/Metabolism Research and Reviews synthesised the mechanisms by which sleep disruption impairs glucose metabolism, appetite regulation, and body composition.9 Insulin resistance develops with striking speed under sleep restriction conditions. Multiple experimental studies using hyperinsulinaemic-euglycaemic clamps — the gold standard for measuring insulin sensitivity — have demonstrated significant reductions in insulin sensitivity after as few as four to five nights of restricted sleep.
The mechanisms are multiple and interacting: decreased brain glucose utilisation, increased sympathetic nervous system activity, HPA axis activation with elevated evening cortisol, alterations in appetite-regulating hormones, elevated inflammatory cytokines, and abnormal adipocyte function.10 Critically, a sleep extension study published in the Journal of Clinical Sleep Medicine found that just three nights of catch-up sleep — extending time in bed from six to ten hours — in chronically sleep-deprived individuals produced approximately a 20% reduction in HOMA-IR.10 This is a clinically meaningful magnitude of effect, achieved through sleep extension alone.
A 2024 Stanford Lifestyle Medicine commentary captured the priority clearly: sleep is "so intertwined with athletic and exercise performance, brain health, and metabolic health" that it represents "a keystone area where many of us can do better and hence reducing our risk for metabolic diseases and lengthening our healthspan."11
For practitioners managing patients with insulin resistance, metabolic syndrome, or unexplained weight gain who are sleeping fewer than seven hours per night, sleep duration and quality should be treated as a primary metabolic intervention target — not an afterthought. The evidence supports sleep optimisation as having a magnitude of effect that rivals many lifestyle and pharmacological approaches.
Appetite Regulation: The Leptin-Ghrelin Disruption
Sleep's effects on appetite operate through a well-characterised hormonal mechanism. Leptin — the satiety hormone — is dependent on sleep duration; short sleep is associated with reduced leptin levels. Simultaneously, sleep restriction elevates ghrelin, the hunger-stimulating hormone. The net effect is a dual hormonal signal promoting increased appetite, reduced satiety, and preferential craving for energy-dense foods — a combination that substantially undermines the effectiveness of dietary interventions in sleep-deprived patients.5
Spiegel et al. demonstrated this in controlled conditions: two nights of sleep restricted to four hours produced measurable increases in ghrelin and decreases in leptin compared to two nights at ten hours — changes associated with increased appetite particularly for high-carbohydrate foods.5 For practitioners observing patients who struggle to adhere to dietary recommendations despite apparent motivation, chronic sleep insufficiency is a biological rather than purely behavioural explanation that warrants clinical attention.
Immune Function and Inflammatory Burden
The immune system is substantially regulated during sleep. A 2025 review in Annals of Neuroscience found that sleep deprivation increases circulating pro-inflammatory cytokines — including IL-6, TNF-α, and CRP — elevates leukocyte and monocyte counts, and impairs natural killer cell activity.12 The relationship between sleep disruption and systemic chronic inflammation is bidirectional and self-amplifying: elevated inflammatory cytokines disrupt sleep architecture, which in turn worsens the inflammatory burden, which further disrupts sleep.
The glymphatic system — the brain's waste-clearance mechanism, which operates primarily during slow-wave sleep — provides a further dimension to this relationship. During sleep, the interstitial space of the brain expands by approximately 60%, allowing cerebrospinal fluid to flush metabolic waste products — including amyloid-beta and tau proteins associated with neurodegeneration — from brain tissue at rates that do not occur during wakefulness.13 Chronic sleep disruption impairs glymphatic clearance, and accumulating evidence links this to elevated neuroinflammation and increased risk of neurodegenerative disease over decades.
Sleep and Longevity: The Ageing Connection
Sleep insufficiency accelerates biological ageing across multiple measurable dimensions. Studies using epigenetic clocks have demonstrated that chronic short sleepers carry older biological ages than their chronological peers. Telomere length is inversely associated with sleep duration and quality in population-level studies. The hallmarks of ageing most directly impacted by sleep include mitochondrial dysfunction, increased cellular senescence, elevated chronic inflammation, and impaired proteostasis — all of which are worsened by sleep insufficiency and partially ameliorated by sleep restoration.13
A 2025 study in Cell Reports found that gut metagenome and plasma metabolome profiles in older adults suggested pyruvate metabolism as a mechanistic link between sleep quality and frailty — connecting the gut microbiome, sleep, mitochondrial function, and ageing in a single biological pathway.14 This level of mechanistic integration is what distinguishes the current state of sleep science from earlier, more descriptive research.
What This Means for Clinical Practice
The emergence of sleep medicine as a clinical discipline reflects a fundamental shift in how medicine understands the relationship between sleep and systemic health — one grounded in mechanisms, not correlations, with direct implications for how practitioners assess and manage patients across virtually every disease category.
The functional medicine model is uniquely well positioned to integrate sleep as a central clinical variable. A systems-biology approach — evaluating sleep in the context of HPA axis function, gut health, inflammatory burden, metabolic markers, and hormonal status — allows practitioners to identify the specific mechanisms through which sleep disruption is driving a patient's presentation, rather than treating it as an independent complaint managed in isolation.
Assessment should extend beyond simple sleep duration. Sleep architecture, sleep continuity, circadian alignment, sleep apnoea screening, and the relationship between sleep quality and daytime functioning all provide clinically meaningful information that duration alone cannot. Validated tools including the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and the STOP-BANG questionnaire for obstructive sleep apnoea provide accessible, evidence-based starting points.
Much of the epidemiological literature on sleep and health outcomes is observational and subject to confounding. Poor sleep is associated with stress, poverty, shift work, and chronic pain — all independently associated with worse health outcomes. Experimental sleep restriction studies in controlled settings provide stronger causal evidence and consistently demonstrate the direction of effect described in this review. Practitioners should be appropriately cautious about overstating mechanistic certainty in individual patient conversations while remaining confident in the overall clinical significance of sleep optimisation.
